ImmunityBio (IBRX) Non Operating Income (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Non Operating Income data on file, last reported at -$563.0 million in Q1 2026.

• On a quarterly basis, Non Operating Income fell 759.92% year-over-year to -$563.0 million in Q1 2026; TTM through Mar 2026 was -$593.1 million, a 517.82% decrease from a year earlier, with the FY2025 full-year figure at -$95.6 million, down 37.6% from the prior year.
• Non Operating Income for Q1 2026 stood at -$563.0 million, down from $2.6 million in the prior quarter.
• Over the last five years, Non Operating Income for IBRX reached as high as $10.2 million in Q4 2024 and fell as low as -$563.0 million in Q1 2026.
• Historically, Non Operating Income has averaged -$59.7 million across 5 years, with a median of -$20.4 million in 2022.
• Across the five-year window, Non Operating Income jumped 106.9% in 2024 and plunged 759.92% in 2026, its largest moves.
• Year by year, Non Operating Income stood at -$23.4 million in 2022, then slumped by 532.97% to -$148.1 million in 2023, then surged by 106.9% to $10.2 million in 2024, then sank by 74.66% to $2.6 million in 2025, then sank by 21837.34% to -$563.0 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were -$563.0 million in Q1 2026, $2.6 million in Q4 2025, and -$11.7 million in Q3 2025.